Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: J Allergy Clin Immunol. 2020 Apr 9;146(4):901–911. doi: 10.1016/j.jaci.2019.11.051

FIG 3.

FIG 3.

Clinical course and survival rate of NFKB1 cohort. A, Cumulative percentage of symptomatic patients who developed infections, autoimmunity, lung disease, and cancer. B, Kaplan-Meier survival curve with 95% CI (dotted lines).